Jump to content

Remogliflozin etabonate

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 12:45, 24 July 2018 (Alter: title. Add: accessdate, issue. Removed parameters. You can use this bot yourself. Report bugs here.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Remogliflozin etabonate
Clinical data
Routes of
administration		Oral
ATC code
  • none
Identifiers
  • 5-Methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
CAS Number
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H38N2O9
Molar mass522.586 g/mol g·mol−1
3D model (JSmol)
  • OC1C(COC(=O)OCC)OC(C(O)C1O)Oc(nn(C(C)C)c2C)c2Cc3ccc(cc3)OC(C)C
  • InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1 ☒N
  • Key:UAOCLDQAQNNEAX-ABMICEGHSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Remogliflozin etabonate (INN/USAN)[1] is a proposed drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin is being developed by Avolynt, Inc.[2]

Clinical trials

Remogliflozin etabonate was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels.[3][4] Remogliflozin etabonate has been studied at doses up to 1000 mg.[5] A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.[6]

Method of action

Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[7] Remogliflozin is selective for SGLT2.

See also

References

  1. ^ Statement on a nonproprietory name adopted by the USAN council
  2. ^ "Avolynt Announces Completion of Phase 2b BRID Study of SGLT2 Inhibitor Remogliflozin-Etabonate" (Press release). Avolynt, Inc. Retrieved July 24, 2018.
  3. ^ Mudaliar, S; Armstrong, DA; Mavian, AA; O'Connor-Semmes, R; Mydlow, PK; Ye, J; Hussey, EK; Nunez, DJ; Henry, RR; Dobbins, RL (Nov 2012). "Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes". Diabetes Care. 35 (11): 2198–200. doi:10.2337/dc12-0508. PMC 3476920. PMID 23011728.
  4. ^ Dobbins, RL; O'Connor-Semmes, R; Kapur, A; Kapitza, C; Golor, G; Mikoshiba, I; Tao, W; Hussey, EK (Jan 2012). "Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients". Diabetes Obes Metab. 14 (1): 15–22. doi:10.1111/j.1463-1326.2011.01462.x. PMID 21733056.
  5. ^ Sykes, AP; O'Connor-Semmes, R; Dobbins, R; Dorey, DJ; Lorimer, JD; Walker, S; Wilkison, WO; Kler, L (Jan 2015). "Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes". Diabetes Obes Metab. 17 (1): 94–7. doi:10.1111/dom.12391. PMID 25223369.
  6. ^ Sykes, AP; Kemp, GL; Dobbins, R; O'Connor-Semmes, R; Almond, SR; Wilkison, WO; Walker, S; Kler, L (Jan 2015). "Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes". Diabetes Obes Metab. 17 (1): 98–101. doi:10.1111/dom.12393. PMID 25238025.
  7. ^ Prous Science: Molecule of the Month November 2007 Archived January 6, 2008, at the Wayback Machine
Retrieved from "https://en.wikipedia.org/w/index.php?title=Remogliflozin_etabonate&oldid=851762036"